Redhill Biopharma Ltd. (RDHL)
NASDAQ
$0.5050−$0.0154 (−2.96%) on the dayAs of the close; data may be delayed.
RDHL price, last 12 months
Key stats
- Previous close
- $0.5204
- Open
- $0.5215
- Day range
- $0.5000 – $0.5303
- 52-week range
- $0.5000 – $2.79
- Volume
- 96K
- Avg volume (20 days)
- 5.6M
- Market cap
- $3.0M
Performance
1W−11.1%
1M−17.9%
3M−42.5%
6M−35.4%
YTD−51.0%
1Y−69.8%
vs S&P 500, 1Y−86.5 pts
Technicals and fundamentals
About Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
- Listed on
- NASDAQ
- Market cap
- $3.0M